Presentation_1_Constitutive Serotonin Tone Modulates Molecular and Behavioral Response to Chronic Fluoxetine Treatment: A Study on Genetic Rat Model.pdf by Maja Kesić (8620716)

“…Platelet 5HT levels, a recognized indicator of SSRI efficacy, were decreased by fluoxetine treatment in both 5HT-sublines. …”

Decreased test sensitivity: Screening the whole population. by Timo de Wolff (9904467)

Supplementary Material for: MicroRNA-125a Correlates with Decreased Psoriasis Severity and Inflammation and Represses Keratinocyte Proliferation by Su F. (4127968)

Inhibition of the mitochondrial fission decreases mtROS production. by Dong Ma (584680)

Subjects:

Video5_Aging, not Parkinson’s disease, decreases a recalibration of body ownership caused by vision-respiratory interaction.MP4 by Daiki Shoji (18283906)

<b>Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice and decrease ISR activation in DRG neurons</b> by Muhammad Saad Yousuf (20745168)

Table_1_Sub-Acute Treatment of Curcumin Derivative J147 Ameliorates Depression-Like Behavior Through 5-HT1A-Mediated cAMP Signaling.DOCX by Jianxin Li (158332)

“…Background<p>Major depressive disorder (MDD) is a severe mental disorder related to the deficiency of monoamine neurotransmitters, particularly to abnormalities of 5-HT (5-hydroxytryptamine, serotonin) and its receptors. …”

Fig 5 - by Maryam Sadat Moezzi (14149432)

Image_5_Evidence for Decreased Density of Calretinin-Immunopositive Neurons in the Caudate Nucleus in Patients With Schizophrenia.TIF by Istvan Adorjan (8466846)

SARS-CoV‑2 Delta Variant Decreases Nanobody Binding and ACE2 Blocking Effectivity by Mert Golcuk (10789806)

SARS-CoV‑2 Delta Variant Decreases Nanobody Binding and ACE2 Blocking Effectivity by Mert Golcuk (10789806)

Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

Subjects:

iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model. by Rahsan Erdem (11726357)

Subjects:

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Subjects:

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 1. by Rahsan Erdem (11726357)

Subjects:

Diarrheal stool output rate overall and by blood type status in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 2. by Rahsan Erdem (11726357)

Subjects: